Friday, 15 Dec 2017

You are here

Skin Remission in Dermatomyositis is Uncommon

JAMA Dermatology reports that clinical remission was relatively uncommon in dermatomyositis, despite aggressive systemic therapy, but was best in those receiving mycophenolate during a 3-year study.

Researchers from Stanford and Johns Hopkins did a prospective cohort study of 74 adults with dermatomyositis,  and included those with a baseline Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score of 12 or higher, and 2 or more CDASI scores separated by 3 months or more within their first 3 years of follow-up.

during a 3-year follow-up period, only 28 patients (38%) achieved clinical skin remission .

Factors associated with remission included:

  • increasing age  (OR 1.07; 95% CI, 1.02-1.12; P = .01)
  • malignancy (OR, 14.46; 95% CI, 2.18-96.07; P = .01)
  • mycophenolate mofetil therapy.  (OR, 6.00; 95% CI, 1.66-21.78; P = .01)

Patients with MDA-5 (anti–melanoma differentiation-associated gene 5) antibodies tended to have the worse outcomes.

Baseline cutaneous disease activity, disease duration at baseline, and disease duration before first systemic therapy were not significantly associated with clinical remission of skin disease.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cochrane Review: Calcium Channel Blocker Efficacy in Raynaud's

The Cochrane Database has published its review of calcium channel blockers (CCB) in Raynaud's phenomenon, showing CCBs may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon, especially with primary Raynaud's.

Fatigue, HAQ and Hand Disability Correlated in Early Systemic Sclerosis

Early diffuse cutaneous systemic sclerosis (SSc) was associated with high levels of disability and fatigue, according to analysis of data from the European Scleroderma Observational Study cohort.

Pregnancy Outcomes Worse with Myopathies

Women with the autoimmune inflammatory myopathies dermatomyositis (DM) and polymyositis (PM) are at increased risk for hypertensive disorders in pregnancy, a nationwide retrospective study found.

Health Economics of SLE

A number of presentations over the past few days have addressed the health economics of SLE.

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease.